Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?

Stock Information for Cytek Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytek Biosciences Inc.

Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora(TM) Evo Flow Cytometer
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
Cytek Biosciences Reports First Quarter 2025 Financial Results
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.